Your browser doesn't support javascript.
loading
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Marloes Grobben; Karlijn van der Straten; Philip J.M. Brouwer; Mitch Brinkkemper; Pauline Maisonnasse; Nathalie Dereuddre-Bosquet; Judith A. Burger; Meliawati Poniman; Melissa Oomen; Dirk Eggink; Tom P.L. Bijl; Hugo D.G. van Willigen; Elke Wynberg; Bas J. Verkaik; Orlane J.A. Figaroa; Peter J. de Vries; Tessel M. Boertien; Roger Le Grand; Menno D. de Jong; Maria Prins; Amy W. Chung; Godelieve J. de Bree; Rogier W. Sanders; Marit J. van Gils.
Afiliação
  • Marloes Grobben; Amsterdam UMC
  • Karlijn van der Straten; Amsterdam UMC
  • Philip J.M. Brouwer; Amsterdam UMC
  • Mitch Brinkkemper; Amsterdam UMC
  • Pauline Maisonnasse; CEA
  • Nathalie Dereuddre-Bosquet; CEA
  • Judith A. Burger; Amsterdam UMC
  • Meliawati Poniman; Amsterdam UMC
  • Melissa Oomen; Amsterdam UMC
  • Dirk Eggink; RIVM
  • Tom P.L. Bijl; Amsterdam UMC
  • Hugo D.G. van Willigen; Amsterdam UMC
  • Elke Wynberg; GGD
  • Bas J. Verkaik; Amsterdam UMC
  • Orlane J.A. Figaroa; Amsterdam UMC
  • Peter J. de Vries; Tergooi Hospital
  • Tessel M. Boertien; Tergooi Hospital
  • Roger Le Grand; CEA
  • Menno D. de Jong; Amsterdam UMC
  • Maria Prins; GGD
  • Amy W. Chung; Peter Doherty Institute
  • Godelieve J. de Bree; Amsterdam UMC
  • Rogier W. Sanders; Amsterdam UMC
  • Marit J. van Gils; Amsterdam UMC
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21256092
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11 to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2 to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 S protein immunization in macaques, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Diagnostic_studies / Rct Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Diagnostic_studies / Rct Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint